Carboplatin-based chemotherapy in patients undergoing hemodialysis

Anticancer Research

Volumn 16, Issue 1, 1996, Pages 533-536

  Yanagawa, Hiroaki ^a,b   Takishita, Yoshihiro ^a   Bando, Hiroyasu ^a   Sumitani, Haruo ^a   Okada, Syuji ^a  

^a TOKUSHIMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Carboplatin; Chemotherapy; Chronic renal failure; Head and neck cancer; Hemodialysis; Lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE;

ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG ADENOCARCINOMA; MALE; PHARYNX CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; HUMANS; INFANT, NEWBORN; KIDNEY FAILURE, CHRONIC; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHARYNGEAL NEOPLASMS; RENAL DIALYSIS;

EID: 0029929524     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Rosenberg B, van Camp L, Trosko JE, Mansour VH: Platinum compound, a new class of potent antitumor agents. Nature 222: 385-386, 1969.
2. Van Echo DA, Egorin MJ, Aisner J: The pharmacology of carboplatin. Semin Oneot 16: 1-6, 1989.
3. Eisenberger M, Hornedo J, Silva H, Donehower R, Spaulding M, Van Echo D: Carboplatin (NSC-241-240): an active platinum analogue for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 4: 1506-1509, 1986.
4. Bonomi PD, Finkelstein DM, Ruckdeschek JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Glick J: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a stuqy of the Eastern Cooperative Oncology Group: J Clin Oncol 7: 102-113, 1989.
5. Klastersky J, Sculier JP, Lacroix H, Dobouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M for the European Organization for Research and Treatment of Cancer Lung Cancer Working Party: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 8: 1556-1562, 1990.
6. Joss RA, Kaplan S, Goldhirsch A, Cristiana S, Brunner KW, Cavalli F: A Phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule: Invest New Drugs 2: 297-304, 1984.
7. Egorin MJ, Van Echo D, Tipping SJ, Olman EA, Whitracre MY, Thompson BW, Aisner J: Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylate) platinum in patients with impaired renal function. Cancer Res 44: 5432-5438, 1984.
8. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: prospective evaluation of a single formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.
9. Farhangi M, Weinstein SH: Carboplatin, etoposide, and bleomycin for treatment of stage IIC seminoma complicated by acute renal failure: Cancer Treat Rep 71: 1123-1124, 1987.
10. Motzer RJ, Niedzwiecki D, Isaacs M, Menendez-Botet C, Tong WP, Flombaum C, Scher HI, Bosl GJ: Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother Pharmacol 27: 234-238, 1990.
11. LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL: Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18. 184-191, 1977.
12. Smith IE, Evans BD, Gore ME, Vincent MD, Repetto L, Yarnold JR, Ford HT: Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small cell lung cancer. J Clin Oncol 5: 185-189, 1987.
13. Gatzemeier U, Hossfeld DK, Nerhauss R, Reck M, Achterrath W, Ienaz L: Combination chemotherapy with carboplatin, etoposide and vincristine as first-line treatment in small cell lung cancer. J Clin Oncol 10: 818-823, 1992.
14. Johnson DH, Hainsworth JD, DeVore R, Hande KR, Greco FA: Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer. Preliminary results of a Vanderbilt trial. Oncology 49: 57-62, 1992.
15. Hartand SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res 44: 1693-1697, 1984.